The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
Circulating tumor cells (CTCs) are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs and forming new tumors. These cells that leave the primary tumor are able to colonize distant organs in the body and initiate the process of metastasis; however, their biology is still not entirely elucidated.
Circulating tumor cells have tremendous utility in cancer research, aiding scientists in deciphering the complex biology of cancer metastasis. Besides the applications in cancer research, the detection and analysis of circulating tumor cells has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. This report is Kalorama's detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies. Analyst Adriana Rusu informs readers of the scientific basis of CTCs in an understandable fashion, and constructs models of revenue opportunity based on several dimensions - application area, cancer type and region - that can assist with business planning efforts.
Despite their potential, the detection and analysis of circulating tumor cells has been a challenging endeavor, and their significance in cancer not completely understood. Progress in the field of CTC-based cancer diagnostics and therapeutics has been thus far hampered by the rarity of these cells and the difficulty to isolate them from the patient’s blood. Nonetheless, in the past decade, numerous technological advances have contributed to a renewed interest in this field. The report considers these challenges and trends in the markets and provides data on the following:
Circulating tumor cells have tremendous utility in cancer research, aiding scientists in deciphering the complex biology of cancer metastasis. Besides the applications in cancer research, the detection and analysis of circulating tumor cells has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. This report is Kalorama's detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies. Analyst Adriana Rusu informs readers of the scientific basis of CTCs in an understandable fashion, and constructs models of revenue opportunity based on several dimensions - application area, cancer type and region - that can assist with business planning efforts.
Despite their potential, the detection and analysis of circulating tumor cells has been a challenging endeavor, and their significance in cancer not completely understood. Progress in the field of CTC-based cancer diagnostics and therapeutics has been thus far hampered by the rarity of these cells and the difficulty to isolate them from the patient’s blood. Nonetheless, in the past decade, numerous technological advances have contributed to a renewed interest in this field. The report considers these challenges and trends in the markets and provides data on the following:
- Introduction and Overview of Biolgy Behind CTCs
- Market and Forecast to 2017 For CTCs-based Technologies
- Market Breakdown by Type of Cancer
- Market Breakdown by Application Type (Research, Diagnostics)
- Market Breakdown by Geographic Region
- Uses in Prognosis, Diagnosis, Drug Development and Other Research
- CTCs-based Products and Competitors
- The Current State of Cancer Treatment, Incidence and Other Helpful Statistics
- Collaboration and Partnerships
- AdnaGen AG
- Advanced Cell Diagnostics, Inc.
- ApoCell, Inc.
- Aviva Biosciences Corporation
- Biocept, Inc.
- BioView Ltd.
- Celula, Inc.
- Clearbridge Biomedics
- Creatv MicroTech, Inc.
- Cynvenio Biosystems
- CytoTrack ApS
- Epic Sciences
- Fluidigm Corporation
- Fluxion Biosciences, Inc.
- Ikonisys, Inc.
- Miltenyi Biotec GmbH
- Parsortix/ANGLE
- RareCells Diagnostics
- ScreenCell
- Silicon Biosystems
- TeloVISION LLC
- Veridex, LLC
- Vitatex Inc.
CHAPTER ONE: EXECUTIVE SUMMARY
Cancer and Circulating Tumor Cells
Current and Potential Clinical Applications of CTCs
CTCs Detection, Isolation and Analysis Technologies
Industry and Market Structure
CHAPTER TWO: CANCER OVERVIEW
Disease Overview
Risk Factors
Incidence of Cancer
CHAPTER THREE: CIRCULATING TUMOR CELLS OVERVIEW
Overview
Characteristics of CTCs
Biology of Circulating Tumor Cells
Current Markers for CTCs Identification and Analysis
Current and Potential Clinical Applications of CTCs
Non-invasive Early Cancer Diagnostic Method
Prognostic Tool for Survival
Therapy Monitoring/ Predictor of Response to Therapy and Selection of Therapy
Drug Development – Selection of Drug Targets/ Selection of Patients
CHAPTER FOUR: CTCS ISOLATION AND DETECTION TECHNOLOGIES
Overview
Enrichment Methods Based on Physical Properties
Conclusions
Immuno-magnetic Capture Methods
Conclusion
Other CTCs Isolation Approaches
Automated Enumeration and Identification of CTCs
Other Automated Scanning/Imaging Methods
Nucleic Acid-Based CTCs Identification Methods
CHAPTER FIVE: INDUSTRY AND MARKET LANDSCAPE
Industry Structure
Competitive Factors
Market Challenges
Product Analysis - CellSearch
Notable Recent Industry Events
Veridex Launched CellSearch system in China
Total Market Revenues and Forecast
COMPANY PROFILES
AdnaGen AG
Advanced Cell Diagnostics, Inc.
ApoCell, Inc.
Aviva Biosciences Corporation
Biocept, Inc.
Biofluidica
BioView Ltd.
Celula, Inc.
Clearbridge Biomedics
Creatv MicroTech, Inc.
Cynvenio Biosystems
CytoTrack ApS
Epic Sciences
Fluidigm Corporation
Fluxion Biosciences, Inc.
Ikonisys, Inc.
Miltenyi Biotec GmbH
On-Q-ity
Parsortix/ANGLE
RareCells Diagnostics
ScreenCell
Silicon Biosystems
TeloVISION LLC
Veridex, LLC
Vitatex Inc.
CHAPTER SEVEN: SELECTED CLINICAL TRIALS INVESTIGATING CIRCULATING TUMOR CELLS IN CANCER PATIENTS
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Skin Cancer
Cancer and Circulating Tumor Cells
Current and Potential Clinical Applications of CTCs
CTCs Detection, Isolation and Analysis Technologies
Industry and Market Structure
CHAPTER TWO: CANCER OVERVIEW
Disease Overview
Risk Factors
Incidence of Cancer
CHAPTER THREE: CIRCULATING TUMOR CELLS OVERVIEW
Overview
Characteristics of CTCs
Biology of Circulating Tumor Cells
Current Markers for CTCs Identification and Analysis
Current and Potential Clinical Applications of CTCs
Non-invasive Early Cancer Diagnostic Method
Prognostic Tool for Survival
Therapy Monitoring/ Predictor of Response to Therapy and Selection of Therapy
Drug Development – Selection of Drug Targets/ Selection of Patients
CHAPTER FOUR: CTCS ISOLATION AND DETECTION TECHNOLOGIES
Overview
Enrichment Methods Based on Physical Properties
Conclusions
Immuno-magnetic Capture Methods
Conclusion
Other CTCs Isolation Approaches
Automated Enumeration and Identification of CTCs
Other Automated Scanning/Imaging Methods
Nucleic Acid-Based CTCs Identification Methods
CHAPTER FIVE: INDUSTRY AND MARKET LANDSCAPE
Industry Structure
Competitive Factors
Market Challenges
Product Analysis - CellSearch
Notable Recent Industry Events
Veridex Launched CellSearch system in China
Total Market Revenues and Forecast
COMPANY PROFILES
AdnaGen AG
Advanced Cell Diagnostics, Inc.
ApoCell, Inc.
Aviva Biosciences Corporation
Biocept, Inc.
Biofluidica
BioView Ltd.
Celula, Inc.
Clearbridge Biomedics
Creatv MicroTech, Inc.
Cynvenio Biosystems
CytoTrack ApS
Epic Sciences
Fluidigm Corporation
Fluxion Biosciences, Inc.
Ikonisys, Inc.
Miltenyi Biotec GmbH
On-Q-ity
Parsortix/ANGLE
RareCells Diagnostics
ScreenCell
Silicon Biosystems
TeloVISION LLC
Veridex, LLC
Vitatex Inc.
CHAPTER SEVEN: SELECTED CLINICAL TRIALS INVESTIGATING CIRCULATING TUMOR CELLS IN CANCER PATIENTS
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Skin Cancer
LIST OF EXHIBITS
CHAPTER TWO: CANCER OVERVIEW
Table 2-1: Top Ten Causes of Death in the World by Geographical Region, 2008
Table 2-2: Top Ten Causes of Death in the World in High Income Countries, 2008
Table 2-3: Top Ten Causes of Death in the World in High Income Countries, 2008
Table 2-4: Global Incidence of Cancer by Geographical Region, 2008
Table 2-5: Global Incidence of Most Common Types of Cancer in Men, 2008
Table 2-6: Global Incidence of Most Common Types of Cancer in Men, 2008
Table 2-7: Global Incidence of Most Common Types of Cancer in Men, 2008
Table 2-8: Projected Growth in Global Incidence of Cancer by Geographical Region, 2008-2030
CHAPTER THREE: CIRCULATING TUMOR CELLS OVERVIEW
Table 3-1: Typical Human Blood Cellular Composition
Figure 3-1: CTC-driven Metastasis Model
Table 3-2: Selected Markers for CTCs Identification and Analysis
Table 3-3: Selected EpCAM-based Methods
Table 3-4: Current and Potential Applications of CTCs in Clinical Practice
CHAPTER FOUR: CTCS ISOLATION AND DETECTION TECHNOLOGIES
Table 4-1: Selected Size and Density-Based CTCs Enrichment Methods
Table 4-2: Selected CTCs Detection and Isolation Methods Based on Electrophysiological Properties
Table 4-3: Selected CTCs Magnetic Platforms Based on Cell Surface Markers
Table 4-4: Selected CTCs Microfluidics Platforms (cont’d.)Table 4-4 (con’d.)
Table 4-5: Selected CTCs Identification Methods Based on Automated Identification and Enumeration
Table 4-6: Selected Nucleic Acid-Based CTCs Identification Methods
CHAPTER FIVE: INDUSTRY AND MARKET LANDSCAPE
Table 5-1: Industry Structure – Selected Competitors and Marketed Products, 2013
Table 5-2: Significant Trends in the CTCs Market, 2013
Figure 5-1: Estimated Market Breakdown, 2012
Figure 5-2: Estimated Market Breakdown by Type of Cancer, 2012
Figure 5-3: Estimated Market Breakdown by Geographical Region, 2012
Table 5-3: Global Market Revenues and Forecast for CTCs-based Technologies ($ Millions), 2011-2017
Figure 5-4: Global Market Revenues and Forecast for CTCs-based Technologies ($ Millions), 2011-2017
Table 5-4: Global Market Revenues for CTCs-based Technologies by Geographical Region ($ Millions), 2011-2017
Figure 5-5: Global Market Revenues for CTCs-based Technologies by Geographical Region ($ Millions), 2011-2017
CHAPTER SEVEN: SELECTED CLINICAL TRIALS INVESTIGATING CIRCULATING TUMOR CELLS IN CANCER PATIENTS
CHAPTER TWO: CANCER OVERVIEW
Table 2-1: Top Ten Causes of Death in the World by Geographical Region, 2008
Table 2-2: Top Ten Causes of Death in the World in High Income Countries, 2008
Table 2-3: Top Ten Causes of Death in the World in High Income Countries, 2008
Table 2-4: Global Incidence of Cancer by Geographical Region, 2008
Table 2-5: Global Incidence of Most Common Types of Cancer in Men, 2008
Table 2-6: Global Incidence of Most Common Types of Cancer in Men, 2008
Table 2-7: Global Incidence of Most Common Types of Cancer in Men, 2008
Table 2-8: Projected Growth in Global Incidence of Cancer by Geographical Region, 2008-2030
CHAPTER THREE: CIRCULATING TUMOR CELLS OVERVIEW
Table 3-1: Typical Human Blood Cellular Composition
Figure 3-1: CTC-driven Metastasis Model
Table 3-2: Selected Markers for CTCs Identification and Analysis
Table 3-3: Selected EpCAM-based Methods
Table 3-4: Current and Potential Applications of CTCs in Clinical Practice
CHAPTER FOUR: CTCS ISOLATION AND DETECTION TECHNOLOGIES
Table 4-1: Selected Size and Density-Based CTCs Enrichment Methods
Table 4-2: Selected CTCs Detection and Isolation Methods Based on Electrophysiological Properties
Table 4-3: Selected CTCs Magnetic Platforms Based on Cell Surface Markers
Table 4-4: Selected CTCs Microfluidics Platforms (cont’d.)Table 4-4 (con’d.)
Table 4-5: Selected CTCs Identification Methods Based on Automated Identification and Enumeration
Table 4-6: Selected Nucleic Acid-Based CTCs Identification Methods
CHAPTER FIVE: INDUSTRY AND MARKET LANDSCAPE
Table 5-1: Industry Structure – Selected Competitors and Marketed Products, 2013
Table 5-2: Significant Trends in the CTCs Market, 2013
Figure 5-1: Estimated Market Breakdown, 2012
Figure 5-2: Estimated Market Breakdown by Type of Cancer, 2012
Figure 5-3: Estimated Market Breakdown by Geographical Region, 2012
Table 5-3: Global Market Revenues and Forecast for CTCs-based Technologies ($ Millions), 2011-2017
Figure 5-4: Global Market Revenues and Forecast for CTCs-based Technologies ($ Millions), 2011-2017
Table 5-4: Global Market Revenues for CTCs-based Technologies by Geographical Region ($ Millions), 2011-2017
Figure 5-5: Global Market Revenues for CTCs-based Technologies by Geographical Region ($ Millions), 2011-2017
CHAPTER SEVEN: SELECTED CLINICAL TRIALS INVESTIGATING CIRCULATING TUMOR CELLS IN CANCER PATIENTS
The idea of a “liquid biopsy” that captures and analyzes CTCs appears to have great advantages for oncology diagnostics and therapeutics. If developed to full potential, CTCs detection and analysis technologies could provide powerful tools to diagnose cancer without the need to collect a tissue specimen from the patient. Despite this, only a limited number of CTCs–based technologies are currently available for oncology practice, due to the lack of robust and highthroughput CTCs detection and isolation technologies.
Presently, the majority of the commercially available technologies for cancer diagnosis and monitoring are able to capture CTCs and count them, thus giving physicians an indication of the disease stage. Current CTC-based diagnostic technologies, such as Veridex’s CellSearch, enable physicians to predict more accurately and earlier than other diagnostic methods the disease progression and survival in cancer patients. Consequently, these technologies permit physicians to select a more appropriate cancer therapy, monitor therapy effectiveness during its administration, and switch patients from ineffective therapies sooner.
However, to enhance their utility in cancer diagnosis and management, CTC-based technologies must also be able to provide information about the origin and genetic characteristics of the captured cells. As tumors are not homogeneous, and their genetic make-up changes during the disease progression and therapy, tissue biopsies may not be able to capture this heterogeneity. The analysis of CTCs has the potential to overcome these limitations; nonetheless, at this time there are many unknowns regarding the exact composition, characteristics, and biological significance of CTCs, fact that underscores the stringent need for functional analysis and molecular characterization of these cells.
